Net loss: US$12.2m (loss widened by 100% from 3Q 2023). US$0.28 loss per share. Revenue exceeded analyst estimates by 10.0%. Earnings per share (EPS) missed analyst estimates by 23%. Looking ahead, ...
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), retaining the price target of $5.75. Joseph Pantginis has given his Buy rating due to ...